A microrna-135a/b binding polymorphism in cd133 confers decreased risk and favorable prognosis of lung cancer in chinese by reducing cd133 expression

Carcinogenesis

Volumn 34, Issue 10, 2013, Pages 2292-2299

  Cheng, Mei ^a   Yang, Lei ^a   Yang, Rongrong ^a   Yang, Xiaorong ^a   Deng, Jieqiong ^b   Yu, Bolan ^a   Huang, Dongsheng ^c   Zhang, Shuxu ^a   Wang, Hui ^a   Qiu, Fuman ^a   Zhou, Yifeng ^b   Lu, Jiachun ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c GUANGZHOU CHEST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; MICRORNA; MICRORNA 135A; MICRORNA 135B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RNA BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

ANTIGENS, CD; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MICRORNAS; PEPTIDES; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK; SURVIVAL ANALYSIS;

EID: 84885092271     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt181     Document Type: Article

References (44)

1. Ferlay, J. et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer, 127, 2893-2917.
2. Jemal, A. et al. (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev., 19, 1893-1907.
3. Siegel, R. et al. (2012) Cancer statistics, 2012. CA. Cancer J. Clin., 62, 10-29.
4. Dick, J.E. (2008) Stem cell concepts renew cancer research. Blood, 112, 4793-4807.
5. Visvader, J.E. et al. (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer, 8, 755-768.
6. Pardal, R. et al. (2003) Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer, 3, 895-902.
7. Al-Hajj, M. et al. (2004) Self-renewal and solid tumor stem cells. Oncogene, 23, 7274-7282.
8. Eramo, A. et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ., 15, 504-514.
9. Rosen, J.M. et al. (2009) The increasing complexity of the cancer stem cell paradigm. Science, 324, 1670-1673.
10. Song, L.L. et al. (2007) Cancer stem cells-an old idea that's new again: implications for the diagnosis and treatment of breast cancer. Expert Opin. Biol. Ther., 7, 431-438.
11. Zhou, B.B. et al. (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov., 8, 806-823.
12. Janikova, M. et al. (2010) Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub., 154, 321-326.
13. Eramo, A. et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ., 15, 504-514.
14. Bertolini, G. et al. (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl Acad. Sci. USA, 106, 16281-16286.
15. Ricci-Vitiani, L. et al. (2007) Identification and expansion of human coloncancer- initiating cells. Nature, 445, 111-115.
16. Ferrandina, G. et al. (2009) CD133 antigen expression in ovarian cancer. BMC Cancer, 9, 221.
17. Bertolini, G. et al. (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl Acad. Sci. USA, 106, 16281-16286.
18. Woo, T. et al. (2010) Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int. J. Clin. Exp. Pathol., 4, 32-42.
19. Artells, R. et al. (2010) Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur. J. Cancer, 46, 642-649.
20. Metellus, P. et al. (2011) Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann. Surg. Oncol., 18, 2937-2945.
21. Sasaki, A. et al. (2010) Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol. Rep., 24, 537-546.
22. Nakamura, M. et al. (2010) Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum. Pathol., 41, 1516-1529.
23. Silva, I.A. et al. (2011) Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res., 71, 3991-4001.
24. Hu, N. et al. (2009) Genomic characterization of esophageal squamous cell carcinoma from a high-risk population in China. Cancer Res., 69, 5908-5917.
25. Feng, B.J. et al. (2002) Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat. Genet., 31, 395-399.
26. Petersen, S. et al. (2000) Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br. J. Cancer, 82, 65-73.
27. Fellay, J. et al.; NIAID Center for HIV/AIDS Vaccine Immunology. (2009) Common genetic variation and the control of HIV-1 in humans. PLoS Genet., 5, e1000791.
28. Wellcome Trust Case Control Consortium. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 447, 661-678.
29. Irvin, M.R. et al. (2011) Genome-wide detection of allele specific copy number variation associated with insulin resistance in African Americans from the HyperGEN study. PLoS One, 6, e24052.
30. Li, Y.J. et al. (2011) Genome-wide association studies reveal genetic variants in CTNND2 for high myopia in Singapore Chinese. Ophthalmology, 118, 368-375.
31. Pohl, A. et al. (2012) Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumabbased chemotherapy. Pharmacogenomics J. doi:10.1038/tpj.2011.61.
32. Okudela, K. et al. (2012) Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma- their prognostic significance. Pathol. Int., 62, 792-801.
33. Liu, B. et al. (2012) A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer. Am. J. Hum. Genet., 91, 384-390.
34. Huang, B. et al. (2012) Functional genetic variants of c-Jun and their interaction with smoking and drinking increase the susceptibility to lung cancer in southern and eastern Chinese. Int. J. Cancer, 131, E744-E758.
35. Yang, L. et al. (2012) A functional polymorphism at microRNA-629-binding site in the 3'-untranslated region of NBS1 gene confers an increased risk of lung cancer in Southern and Eastern Chinese population. Carcinogenesis, 33, 338-347.
36. Lu, J. et al. (2011) The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in Southern and Eastern Chinese populations. Hum. Mutat., 32, 1299-1308.
37. Liu, J.Z. et al.; AMFS Investigators. (2010) A versatile gene-based test for genome-wide association studies. Am. J. Hum. Genet., 87, 139-145.
38. Elsaba, T.M. et al. (2010) The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS One, 5, e10714.
39. Vaughan, A.E. et al. (2012) Lung cancer in mice induced by the jaagsiekte sheep retrovirus envelope protein is not maintained by rare cancer stem cells, but tumorigenicity does correlate with Wnt pathway activation. Mol. Cancer Res., 10, 86-95.
40. Cortes-Dericks, L. et al. (2012) High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals. Eur. J. Cardiothorac. Surg., 41, e173-e181.
41. Yang, Z.L. et al. (2011) Upregulated CD133 expression in tumorigenesis of colon cancer cells. World J. Gastroenterol., 17, 932-937.
42. Wang, S. et al. (2013) CD133+ cancer stem cells in lung cancer. Front. Biosci., 18, 447-453.
43. Wu, S. et al. (2012) MiR-135a functions as a selective killer of malignant glioma. Oncogene, 31, 3866-3874.
44. Hu, Z. et al. (2011) A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat. Genet., 43, 792-796.